Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 1Ovarian Neoplasms 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

pembrolizumab 37Carboplatin 31Cisplatin 30Paclitaxel 23Nivolumab 21Pemetrexed 21Dexamethasone 18Gemcitabine 18Ipilimumab 15Docetaxel 13Fluorouracil 13Capecitabine 12Rituximab 12Cyclophosphamide 10Cytarabine 10Trastuzumab 9atezolizumab 9daratumumab 9olaparib 9130-nm albumin-bound paclitaxel 8Lenalidomide 8Prednisone 8durvalumab 8trastuzumab deruxtecan 8Bevacizumab 7Bortezomib 7Fulvestrant 7Oxaliplatin 7Vinorelbine 7cabozantinib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Has announcements × Glucose × Clear all
NCT05116189 2026-03-09

KEYNOTE-B96

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
643 enrolled 17 charts 1 FDA
Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡